INVASIVE PROCEDURES IN PATIENTS WITH HAEMOPHILIA ON EMICIZUMAB PROPHYLAXIS: REAL-WORLD CLINICAL EXPERIENCE IN SLOVENIA

被引：0
|
作者：
Rener, K. [1 ]
Pompe, B. [2 ]
Doma, S. Anzej [1 ]
Kotnik, B. Faganel [3 ]
Kitanovski, L. [3 ]
Zupan, I. Preloznik [1 ]
机构：
[1] Univ Med Ctr Ljubljana, Haematol, Ljubljana, Slovenia
[2] Univ Med Ctr Ljubljana, Orthoped Surg, Ljubljana, Slovenia
[3] Univ Med Ctr Ljubljana, Div Paediat, Ljubljana, Slovenia
来源：
HAEMOPHILIA | 2022年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PO082
引用
收藏
页码：66 / 66
页数：1
相关论文
共 50 条
  • [31] Real world experience with Emicizumab in severe haemophilia A (HA) in Senegal, West Africa
    Diop, Saliou
    Seck, Moussa
    Mbomboa, Safiya
    Martin, Jayson
    Toure, Sokhna Aissatou
    Senghor, Alioune Badara
    Bousso, Elimane Seydi
    Keita, Mohamed
    Diallo, Alioune Badara
    Faye, Blaise Felix
    Sy, Diariatou
    Haffar, Assad
    HAEMOPHILIA, 2022, 28 : 69 - 70
  • [32] Real-world data for the use of emicizumab in haemophilia A patients with inhibitors - First nationwide report from Korea
    Hahn, Seung Min
    Han, Jung Woo
    Kim, Jin Seok
    Shim, Ye Jee
    Kim, Soyon
    Kim, Hugh Chul
    Park, Young Shil
    Lyu, Chuhl Joo
    HAEMOPHILIA, 2023, 29 (04) : 1163 - 1166
  • [33] Management and outcomes of paediatric patients on emicizumab prophylaxis undergoing surgical procedures: Experience from a large haemophilia centre in the UK
    Hassan, Eman
    Motwani, Jayashree
    HAEMOPHILIA, 2021, 27 (05) : E620 - E623
  • [34] Real-World Clinical and Laboratory Characteristics in Severe Hemophilia a Patients Commencing Emicizumab
    Ling, Gavin
    Ajidahun, Aderonke
    Austin, Steve K.
    Dolan, Gerard
    McCormick, Aine
    BLOOD, 2020, 136
  • [35] Emicizumab prophylaxis in infants with severe haemophilia A without inhibitors: Illustrative real-world cases to support shared decision-making
    Mason, Jane A.
    Young, Guy
    HAEMOPHILIA, 2021, 27 (05) : 724 - 729
  • [36] Personalized Prophylaxis with myPKFiTCE: A Real-World Cost-Effectiveness Analysis in Haemophilia A Patients
    Antonazzo, Ippazio Cosimo
    Cortesi, Paolo Angelo
    Zanon, Ezio
    Pasca, Samantha
    Morfini, Massimo
    Santoro, Cristina
    De Cristofaro, Raimondo
    Di Minno, Giovanni
    Cozzolino, Paolo
    Mantovani, Lorenzo Giovanni
    MEDICINA-LITHUANIA, 2024, 60 (01):
  • [37] Safety of recombinant activated factor VII for treatment of breakthrough bleeds in patients with congenital haemophilia A and inhibitors receiving emicizumab prophylaxis: Review of the real-world evidence
    Kenet, Gili
    Fujii, Teruhisa
    HAEMOPHILIA, 2024, 30 (02) : 267 - 275
  • [38] Management and Outcomes of Invasive Procedures in Individuals with Hemophilia A on Emicizumab Prophylaxis: A Single Center Experience
    Rener, Karla
    Anzej Doma, Sasa
    Fink, Martina
    Podgornik, Helena
    Preloznik Zupan, Irena
    Cerchione, Claudio
    Zanon, Ezio
    HEMATOLOGY REPORTS, 2023, 15 (04) : 597 - 607
  • [39] Emicizumab prophylaxis: Prospective longitudinal real-world follow-up and monitoring
    Barg, Assaf A.
    Budnik, Ivan
    Avishai, Einat
    Brutman-Barazani, Tami
    Bashari, Dalia
    Misgav, Mudi
    Lubetsky, Aaron
    Kuperman, Amir A.
    Livnat, Tami
    Kenet, Gili
    HAEMOPHILIA, 2021, 27 (03) : 383 - 391
  • [40] Real-world clinical experience of switching to rVIII-SingleChain in adults/adolescents and paediatric patients with haemophilia A
    Goldmann, G.
    Olivieri, M.
    Oldenburg, J.
    Kurnik, K.
    Bidlingmaier, C.
    HAEMOPHILIA, 2019, 25 : 68 - 69
12345